---
document_datetime: 2026-01-26 11:59:31
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/kisqali-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: kisqali-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.8433174
conversion_datetime: 2026-01-29 12:30:46.122358
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Kisqali

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IA /  | This was an application for a group of | 23/01/2026                          |                                             | Annex II and                     |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000323497   | PL   |
|---------------------|------|

<div style=\"page-break-after: always\"></div>

|                                          | batch release, site where batch control takes place, or supplier of a starting material, reagent or excipient (when mentioned in the dossier)* - Accepted                                                                                                                                                                                                                             |            |            |                        |           |
|------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|-----------|
| Variation type IA_IN / EMA/VR/0000303549 | B.II.g.5 Implementation of changes foreseen in an approved change management protocol - B.II.g.5.a The implementation of the change requires no further supportive data - Accepted                                                                                                                                                                                                    | 20/10/2025 |            | SmPC                   |           |
| PSUR / EMA/PSUR/0000274416               | In view of available data on autoimmune hepatitis from clinical trials, the literature, spontaneous reports including in some cases a close temporal relationship and a positive de-challenge, the PRAC considers a causal relationship between ribociclib and autoimmune hepatitis is at least a reasonable possibility. The PRAC concluded that the product information of products | 16/10/2025 | 19/12/2025 | SmPC and PL            | Variation |
| Variation type II / EMA/VR/0000269890    | This was an application for a group of variations. B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.b Substantial changes to a manufacturing process that                                                                                                                   | 18/09/2025 | 19/12/2025 | SmPC, Labelling and PL |           |

<div style=\"page-break-after: always\"></div>

| may have a significant impact on the quality, safety and efficacy of the medicinal product - Accepted B.II.b.5 Change to in-process tests or limits applied during the manufacture of the finished product - B.II.b.5.b Addition of a new test(s) and limits - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.1 As packaged for sale (supported by real time data) - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.d Change in storage conditions of the finished product or the diluted/reconstituted product - Accepted B.II.f.1 Change in the shelf-life or storage conditions of the finished product - B.II.f.1.e Change to an approved stability protocol - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Change in the   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                                       | parameters and/or limits of the finished product - B.II.d.1.a Tightening of specification limits - Accepted B.II.g) Design Space and post approval change management protocol - B.II.g.2 Introduction of a post approval change management protocol related to the finished product - Accepted                                                                                |            |            |      |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|
| Variation type IB / EMA/VR/0000261091 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Implementation of an agreed wording, no new data submitted - Accepted C.I.z - To update section 5.1 of the SmPC by removing the words \"(excluding microscopic nodal involvement)\" since this wording inaccurately reflects the population included in the Pivotal clinical trial (Procedure No. EMEA/H/C/004213/II/0045). | 24/04/2025 | 19/12/2025 | SmPC |